FDA Approves Voceryq for Recurrent Respiratory Papillomatosis (RRP)

• The FDA has granted accelerated approval to Voceryq, the first plasmid DNA-based immunotherapy, for treating adults with recurrent respiratory papillomatosis (RRP).
• Voceryq targets the root cause of RRP, a rare disease caused by HPV types 6 and 11, which leads to wart-like growths in the airways.
• Clinical trial data showed Voceryq reduced the frequency of surgical interventions in adult RRP patients.
• The therapy is administered via intramuscular injection using a specialized device that facilitates electroporation for cellular delivery.
• This accelerated approval mandates the manufacturer to conduct post-approval clinical trials to verify and fully describe Voceryq's clinical benefit.

A crucial condition of this approval is that the manufacturer is mandated to conduct post-approval clinical trials.

The U.S. Food and Drug Administration (FDA) has recently granted accelerated approval to Voceryq, known by its full designation doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd. This innovative therapy is indicated for the treatment of adults afflicted with recurrent respiratory papillomatosis (RRP), a rare condition stemming from human papillomavirus (HPV) infection that results in the formation of small, wart-like growths within the patient's airways.

This landmark decision marks the first time a plasmid DNA-based immunotherapy has received approval in the United States. Voceryq introduces a new therapeutic avenue for patients, directly addressing the underlying cause of RRP. Its introduction is expected to alleviate the significant burden of repeated surgical interventions, representing a crucial advancement for a patient population that has historically faced extremely limited treatment options. The FDA highlighted that for individuals living with RRP, who often endure a relentless cycle of surgeries, this approval signifies a meaningful scientific breakthrough that could lead to fewer medical procedures and a better quality of life.

Recurrent respiratory papillomatosis is a chronic and uncommon disease characterized by the development of wart-like growths, termed papillomas, within the respiratory tract. These growths are specifically caused by human papillomavirus types 6 and/or 11 and frequently appear in the larynx, particularly on the vocal cords. Patients commonly experience symptoms such as hoarseness, a persistent cough, and alterations in their voice.

In more severe instances, these papillomas can spread to other regions of the respiratory system, potentially leading to significant breathing difficulties. While surgical removal of these growths is a common treatment approach, it does not offer a cure, as the virus continues to reside in the tissue even after the papillomas are excised. Consequently, individuals with RRP often require numerous surgical procedures over many years. Furthermore, RRP carries an inherent risk of malignant transformation over time.

Voceryq functions as a recombinant plasmid DNA-based immunotherapy, delivering two distinct plasmids, which are small DNA fragments originally derived from bacteria, into the body's cells. One of these plasmids carries the genetic blueprint for specific HPV proteins, while the other contains an immune response-enhancing molecule known as IL-12. The therapy is engineered to stimulate the immune system, prompting it to recognize and attack cells infected by the particular HPV types (6 and 11) responsible for RRP.

Administration of Voceryq occurs via intramuscular injection, utilizing the CELLECTRA 5PSP Device. This device not only delivers the precise dose but also facilitates electroporation, a technique that employs brief electrical pulses to temporarily and reversibly create pores in cell membranes, thereby enabling the efficient uptake of Voceryq into the cells. The safety and effectiveness of Voceryq were rigorously assessed in an open-label, multicenter clinical trial involving 32 adult patients diagnosed with RRP. Eligible participants had undergone at least two surgeries to remove laryngotracheal papillomas within the 12 months preceding Voceryq treatment. A notable outcome from the trial indicated that seven out of 26 patients (27%) who had a minimum of three baseline surgeries did not require any further surgical intervention during the initial year following treatment. The most frequently reported adverse reactions included injection site reactions, headache, fatigue, hypertension, nausea, and dizziness.

The FDA's decision to grant accelerated approval for Voceryq was predicated on clinical trial data demonstrating a reduction in the frequency of surgical procedures required for adult RRP patients. This observed decrease in surgical burden served as an intermediate clinical endpoint, which the agency deemed reasonably likely to predict a tangible clinical benefit for patients.

The accelerated approval pathway is a specialized regulatory mechanism designed to expedite the availability of drugs and biologics for serious or life-threatening conditions, allowing approval based on surrogate or intermediate endpoints. A crucial condition of this approval is that the manufacturer is mandated to conduct post-approval clinical trials. These ongoing studies are essential to definitively verify and comprehensively describe the full clinical benefit of Voceryq, placing significant regulatory obligations on the manufacturer to ensure continuous monitoring and adherence to FDA requirements for confirming the drug's long-term efficacy and safety.

Compliance officers and regulatory lawyers in pharmaceutical companies should note this accelerated approval of Voceryq, which necessitates ongoing post-market clinical trials to verify and describe its clinical benefit. This creates specific regulatory obligations and potential liabilities for the manufacturer, requiring careful monitoring and adherence to FDA requirements.

Source: Original reporting via FDA press release